Latest News for: hypoxic tumor

Edit

Colorectal Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, ...

GetNews 26 Mar 2025
Ompenaclid is a first in class oral small molecule inhibitor of the creatine transport channel SLC6A8 a novel target that is enriched under hypoxic conditions and provides tumor cells with an additional energy source.
  • 1
×